pasitheaclinics.com (KTTA): Multiplikator forward rega marang pendapatan

Pasithea Therapeutics focuses on developing RNA therapies to combat mental disorders. The GURU.Markets service provides this chart, where the forward P/S indicator demonstrates volatility, while the 39.40 mark indicates the current valuation level. Geopolitics are hindering international trials and reagent procurement, while a lack of profitability and reliance on venture capital investments deprive the company of pricing power.

Forward P/S determines the market value of a business relative to expected sales volume, allowing for an assessment of the premium paid for future cash flows. By analyzing the forward P/S trend, an investor can see the speculative nature of the valuation of Pasithea Therapeutics (KTTA), whose capitalization is based on venture expectations from neuropsychiatric clinical trials rather than the actual presence of stable revenue.